TFRC and cancer: Encapsulated Neq0554 demonstrated enhanced anticancer activity in vitro compared to naked agent (3-fold), revealing cancer cell line-selectivity (2.5-fold), possible consequence of enhanced TfR-1-mediated endocytosis of AFt-Neq0554.